Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed rapid improvement, with nearly two-thirds achieving key hemoglobin targets by Week 24, along with reduced fatigue and steroid use. The drug works by blocking the neonatal Fc receptor to reduce harmful antibodies while preserving immune function. These positive results support the FDA's Priority Review of IMAAVY's supplemental Biologics License Application, potentially advancing treatment options for this rare disorder.
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable...
The SNPD ETF focuses on companies with long histories of increasing dividends, such as Johnson & Johnson, Coca-Cola, Procter & Gamble, PepsiCo, and Lowe's. These companies have strong free cash flow coverage supporting their payouts, making SNPD's di...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
